BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Feagan BG, Marabani M, Wu JJ, Faccin F, Spronk C, Castañeda-Hernández G. The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence. Adv Ther 2020;37:4491-518. [PMID: 32910420 DOI: 10.1007/s12325-020-01472-1] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Park JP, Jung B, Park HK, Shin D, Jung JA, Ghil J, Han J, Kim KA, Woollett GR. Interchangeability for Biologics is a Legal Distinction in the USA, Not a Clinical One. BioDrugs 2022. [PMID: 35696067 DOI: 10.1007/s40259-022-00538-6] [Reference Citation Analysis]
2 Lin I, Melsheimer R, Bhak RH, Lefebvre P, DerSarkissian M, Emond B, Lax A, Nguyen C, Wu M, Young-Xu Y. Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. Curr Med Res Opin 2022;:1-33. [PMID: 35125053 DOI: 10.1080/03007995.2022.2037846] [Reference Citation Analysis]
3 Findeisen KE, Sewell J, Ostor AJK. Biological Therapies for Rheumatoid Arthritis: An Overview for the Clinician. Biologics 2021;15:343-52. [PMID: 34413630 DOI: 10.2147/BTT.S252575] [Reference Citation Analysis]
4 Kurki P, Barry S, Bourges I, Tsantili P, Wolff-Holz E. Safety, Immunogenicity and Interchangeability of Biosimilar Monoclonal Antibodies and Fusion Proteins: A Regulatory Perspective. Drugs 2021;81:1881-96. [PMID: 34596876 DOI: 10.1007/s40265-021-01601-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Finck B, Geller RB, Walden P. Letter to the Editor Regarding "The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence". Adv Ther 2021;38:3483-6. [PMID: 33914268 DOI: 10.1007/s12325-021-01694-x] [Reference Citation Analysis]
6 Teran E, Gomez H, Hannois D, Lema M, Mantilla W, Rico-restrepo M, Mcelwee E, Castro Sanchez N, Valdivieso N, Espinoza MA. Streamlining breast cancer and colorectal cancer biosimilar regulations to improve treatment access in Latin America: an expert panel perspective. The Lancet Oncology 2022;23:e348-58. [DOI: 10.1016/s1470-2045(22)00121-8] [Reference Citation Analysis]
7 Luber RP, O'Neill R, Singh S, Sharma E, Cunningham G, Honap S, Meade S, Ray S, Anderson SH, Mawdsley J, Sanderson JD, Samaan MA, Arkir Z, Irving PM. An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch. Aliment Pharmacol Ther 2021;54:678-88. [PMID: 34223654 DOI: 10.1111/apt.16497] [Reference Citation Analysis]
8 Rathore AS, Stevenson JG, Chhabra H, Maharana C. The global landscape on interchangeability of biosimilars. Expert Opin Biol Ther 2021;:1-16. [PMID: 33567923 DOI: 10.1080/14712598.2021.1889511] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Papautsky EL, Carlson M, Johnson SM, Montague H, Attai DJ, Lustberg MB. Characterizing experiences of non-medical switching to trastuzumab biosimilars using data from internet-based surveys with US-based oncologists and breast cancer patients. Breast Cancer Res Treat 2022. [PMID: 35568748 DOI: 10.1007/s10549-022-06615-2] [Reference Citation Analysis]
10 Karlsdottir K, Gunnarsdottir AI, Grondal G, Love TJ, Stefansdottir E, Davidsdottir LG, Thorleifsdottir RH, Gudbjornsson B. A Patients' Perspective Towards the Injection Devices for Humira® and Imraldi® in a Nationwide Switching Program. Front Med 2022;9:799494. [DOI: 10.3389/fmed.2022.799494] [Reference Citation Analysis]
11 García-Beloso N, Altabás-González I, Samartín-Ucha M, Gayoso-Rey M, De Castro-Parga ML, Salgado-Barreira Á, Cibeira-Badia A, Piñeiro-Corrales MG, González-Vilas D, Pego-Reigosa JM, Martínez-López de Castro N. Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: A systematic literature review. Br J Clin Pharmacol 2021. [PMID: 34622969 DOI: 10.1111/bcp.15101] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Stavem K. Switching from one reference biological to another in stable patients for non-medical reasons: a literature search and brief review. J Mark Access Health Policy 2021;9:1964792. [PMID: 34434534 DOI: 10.1080/20016689.2021.1964792] [Reference Citation Analysis]